AEON Biopharma receives FDA Type 2b minutes; plans IND for CMAP PD study, warrants to accelerate
AEON Biopharma received FDA Type 2b meeting minutes that support advancing ABP-450 toward a 351(k) BLA and plans to file an IND for a CMAP PD study in Q4 2026.Key Highlights:Original SEC Filing: AEON Biopharma, Inc. [ AEON ] - 8-K - Sep. 30, 2026This is an AI-powered summary. It may contain inaccur…